nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Propranolol—Carteolol—glaucoma	0.141	0.276	CrCrCtD
Duloxetine—Propranolol—Levobunolol—glaucoma	0.141	0.276	CrCrCtD
Duloxetine—Propranolol—Metipranolol—glaucoma	0.134	0.263	CrCrCtD
Duloxetine—Propranolol—Betaxolol—glaucoma	0.0939	0.184	CrCrCtD
Duloxetine—SLC6A2—Clonidine—glaucoma	0.0527	0.225	CbGbCtD
Duloxetine—CYP2D6—Carteolol—glaucoma	0.0427	0.182	CbGbCtD
Duloxetine—CYP1A2—Betaxolol—glaucoma	0.035	0.149	CbGbCtD
Duloxetine—CYP2D6—Betaxolol—glaucoma	0.0288	0.123	CbGbCtD
Duloxetine—CYP2D6—Methazolamide—glaucoma	0.0218	0.0931	CbGbCtD
Duloxetine—CYP1A2—Clonidine—glaucoma	0.0192	0.0817	CbGbCtD
Duloxetine—CYP2D6—Timolol—glaucoma	0.0186	0.0792	CbGbCtD
Duloxetine—CYP2D6—Clonidine—glaucoma	0.0158	0.0673	CbGbCtD
Duloxetine—CYP2D6—Melatonin metabolism and effects—APOE—glaucoma	0.000124	0.0026	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000124	0.00259	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—EDN1—glaucoma	0.000124	0.00259	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000118	0.00247	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HEYL—glaucoma	0.000116	0.00244	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GSTM1—glaucoma	0.000116	0.00243	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000115	0.00242	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000115	0.00241	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000113	0.00237	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—glaucoma	0.000113	0.00237	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTGFR—glaucoma	0.000113	0.00236	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—OPN4—glaucoma	0.000112	0.00235	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL1A—glaucoma	0.00011	0.00232	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.00011	0.00231	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—glaucoma	0.00011	0.00231	CbGpPWpGaD
Duloxetine—CYP1A2—Tryptophan metabolism—CYP1B1—glaucoma	0.00011	0.00231	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—C3—glaucoma	0.000108	0.00226	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NGFR—glaucoma	0.000108	0.00226	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000105	0.00221	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—APOE—glaucoma	0.000105	0.0022	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000104	0.00219	CbGpPWpGaD
Duloxetine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000104	0.00218	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000103	0.00216	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NTRK1—glaucoma	0.000102	0.00215	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—NGF—glaucoma	0.000102	0.00214	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000101	0.00213	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTGFR—glaucoma	0.000101	0.00212	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.0001	0.0021	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GSTM1—glaucoma	9.95e-05	0.00209	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—OPN4—glaucoma	9.73e-05	0.00204	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—SMO—glaucoma	9.61e-05	0.00202	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—SLC6A1—glaucoma	9.47e-05	0.00199	CbGpPWpGaD
Duloxetine—Arrhythmia—Betaxolol—glaucoma	9.29e-05	0.000447	CcSEcCtD
Duloxetine—Feeling abnormal—Dorzolamide—glaucoma	9.27e-05	0.000446	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NTRK2—glaucoma	9.27e-05	0.00194	CbGpPWpGaD
Duloxetine—Decreased appetite—Pilocarpine—glaucoma	9.24e-05	0.000444	CcSEcCtD
Duloxetine—Feeling abnormal—Travoprost—glaucoma	9.23e-05	0.000444	CcSEcCtD
Duloxetine—Conjunctivitis—Timolol—glaucoma	9.2e-05	0.000443	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dorzolamide—glaucoma	9.2e-05	0.000442	CcSEcCtD
Duloxetine—Alopecia—Betaxolol—glaucoma	9.19e-05	0.000442	CcSEcCtD
Duloxetine—Palpitations—Clonidine—glaucoma	9.19e-05	0.000442	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Pilocarpine—glaucoma	9.18e-05	0.000441	CcSEcCtD
Duloxetine—Gastrointestinal pain—Travoprost—glaucoma	9.16e-05	0.000441	CcSEcCtD
Duloxetine—Loss of consciousness—Clonidine—glaucoma	9.14e-05	0.00044	CcSEcCtD
Duloxetine—Feeling abnormal—Brinzolamide—glaucoma	9.12e-05	0.000438	CcSEcCtD
Duloxetine—Mental disorder—Betaxolol—glaucoma	9.11e-05	0.000438	CcSEcCtD
Duloxetine—Pain—Pilocarpine—glaucoma	9.09e-05	0.000437	CcSEcCtD
Duloxetine—Constipation—Pilocarpine—glaucoma	9.09e-05	0.000437	CcSEcCtD
Duloxetine—Cough—Clonidine—glaucoma	9.08e-05	0.000437	CcSEcCtD
Duloxetine—Dizziness—Apraclonidine—glaucoma	9.07e-05	0.000436	CcSEcCtD
Duloxetine—Malnutrition—Betaxolol—glaucoma	9.06e-05	0.000436	CcSEcCtD
Duloxetine—Erythema—Betaxolol—glaucoma	9.06e-05	0.000436	CcSEcCtD
Duloxetine—Urticaria—Dorzolamide—glaucoma	8.94e-05	0.00043	CcSEcCtD
Duloxetine—Epistaxis—Timolol—glaucoma	8.93e-05	0.000429	CcSEcCtD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	8.91e-05	0.00187	CbGpPWpGaD
Duloxetine—Abdominal pain—Dorzolamide—glaucoma	8.89e-05	0.000428	CcSEcCtD
Duloxetine—Body temperature increased—Dorzolamide—glaucoma	8.89e-05	0.000428	CcSEcCtD
Duloxetine—Tension—Betaxolol—glaucoma	8.89e-05	0.000427	CcSEcCtD
Duloxetine—Dysgeusia—Betaxolol—glaucoma	8.87e-05	0.000427	CcSEcCtD
Duloxetine—Chest pain—Clonidine—glaucoma	8.86e-05	0.000426	CcSEcCtD
Duloxetine—Arthralgia—Clonidine—glaucoma	8.86e-05	0.000426	CcSEcCtD
Duloxetine—Abdominal pain—Travoprost—glaucoma	8.86e-05	0.000426	CcSEcCtD
Duloxetine—Anxiety—Clonidine—glaucoma	8.83e-05	0.000424	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—RPTOR—glaucoma	8.81e-05	0.00185	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GSTM1—glaucoma	8.81e-05	0.00185	CbGpPWpGaD
Duloxetine—Asthenia—Acetazolamide—glaucoma	8.81e-05	0.000424	CcSEcCtD
Duloxetine—Dizziness—Bimatoprost—glaucoma	8.8e-05	0.000423	CcSEcCtD
Duloxetine—Nervousness—Betaxolol—glaucoma	8.8e-05	0.000423	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	8.8e-05	0.000423	CcSEcCtD
Duloxetine—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—glaucoma	8.79e-05	0.00184	CbGpPWpGaD
Duloxetine—Urticaria—Brinzolamide—glaucoma	8.79e-05	0.000423	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—PTGFR—glaucoma	8.76e-05	0.00184	CbGpPWpGaD
Duloxetine—Feeling abnormal—Pilocarpine—glaucoma	8.76e-05	0.000421	CcSEcCtD
Duloxetine—Discomfort—Clonidine—glaucoma	8.75e-05	0.000421	CcSEcCtD
Duloxetine—Vomiting—Apraclonidine—glaucoma	8.73e-05	0.00042	CcSEcCtD
Duloxetine—Muscle spasms—Betaxolol—glaucoma	8.71e-05	0.000419	CcSEcCtD
Duloxetine—Gastrointestinal pain—Pilocarpine—glaucoma	8.69e-05	0.000418	CcSEcCtD
Duloxetine—Hypersensitivity—Brimonidine—glaucoma	8.68e-05	0.000417	CcSEcCtD
Duloxetine—Dry mouth—Clonidine—glaucoma	8.66e-05	0.000417	CcSEcCtD
Duloxetine—Dermatitis—Apraclonidine—glaucoma	8.64e-05	0.000416	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—OPN4—glaucoma	8.6e-05	0.00181	CbGpPWpGaD
Duloxetine—Headache—Apraclonidine—glaucoma	8.6e-05	0.000413	CcSEcCtD
Duloxetine—Confusional state—Clonidine—glaucoma	8.56e-05	0.000412	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—NCK2—glaucoma	8.54e-05	0.00179	CbGpPWpGaD
Duloxetine—Vision blurred—Betaxolol—glaucoma	8.54e-05	0.000411	CcSEcCtD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	8.52e-05	0.00179	CbGpPWpGaD
Duloxetine—Oedema—Clonidine—glaucoma	8.49e-05	0.000408	CcSEcCtD
Duloxetine—Tremor—Betaxolol—glaucoma	8.49e-05	0.000408	CcSEcCtD
Duloxetine—Hallucination—Timolol—glaucoma	8.46e-05	0.000407	CcSEcCtD
Duloxetine—Asthenia—Brimonidine—glaucoma	8.45e-05	0.000407	CcSEcCtD
Duloxetine—Infection—Clonidine—glaucoma	8.43e-05	0.000406	CcSEcCtD
Duloxetine—Abdominal pain—Pilocarpine—glaucoma	8.4e-05	0.000404	CcSEcCtD
Duloxetine—Body temperature increased—Pilocarpine—glaucoma	8.4e-05	0.000404	CcSEcCtD
Duloxetine—Ill-defined disorder—Betaxolol—glaucoma	8.4e-05	0.000404	CcSEcCtD
Duloxetine—Diarrhoea—Acetazolamide—glaucoma	8.4e-05	0.000404	CcSEcCtD
Duloxetine—Rash—Bimatoprost—glaucoma	8.39e-05	0.000403	CcSEcCtD
Duloxetine—Dermatitis—Bimatoprost—glaucoma	8.38e-05	0.000403	CcSEcCtD
Duloxetine—Oedema peripheral—Timolol—glaucoma	8.37e-05	0.000403	CcSEcCtD
Duloxetine—Anaemia—Betaxolol—glaucoma	8.37e-05	0.000403	CcSEcCtD
Duloxetine—Shock—Clonidine—glaucoma	8.35e-05	0.000402	CcSEcCtD
Duloxetine—Connective tissue disorder—Timolol—glaucoma	8.35e-05	0.000402	CcSEcCtD
Duloxetine—Pruritus—Brimonidine—glaucoma	8.34e-05	0.000401	CcSEcCtD
Duloxetine—Headache—Bimatoprost—glaucoma	8.34e-05	0.000401	CcSEcCtD
Duloxetine—Nervous system disorder—Clonidine—glaucoma	8.33e-05	0.0004	CcSEcCtD
Duloxetine—Thrombocytopenia—Clonidine—glaucoma	8.31e-05	0.0004	CcSEcCtD
Duloxetine—Hypersensitivity—Dorzolamide—glaucoma	8.29e-05	0.000399	CcSEcCtD
Duloxetine—Tachycardia—Clonidine—glaucoma	8.29e-05	0.000399	CcSEcCtD
Duloxetine—Hypersensitivity—Travoprost—glaucoma	8.25e-05	0.000397	CcSEcCtD
Duloxetine—Skin disorder—Clonidine—glaucoma	8.25e-05	0.000397	CcSEcCtD
Duloxetine—CYP1A2—Phase II conjugation—GSTT1—glaucoma	8.23e-05	0.00173	CbGpPWpGaD
Duloxetine—Hyperhidrosis—Clonidine—glaucoma	8.21e-05	0.000395	CcSEcCtD
Duloxetine—Visual impairment—Timolol—glaucoma	8.19e-05	0.000394	CcSEcCtD
Duloxetine—Malaise—Betaxolol—glaucoma	8.17e-05	0.000393	CcSEcCtD
Duloxetine—Nausea—Apraclonidine—glaucoma	8.15e-05	0.000392	CcSEcCtD
Duloxetine—Hypersensitivity—Brinzolamide—glaucoma	8.15e-05	0.000392	CcSEcCtD
Duloxetine—Vertigo—Betaxolol—glaucoma	8.14e-05	0.000391	CcSEcCtD
Duloxetine—Syncope—Betaxolol—glaucoma	8.12e-05	0.000391	CcSEcCtD
Duloxetine—Dizziness—Acetazolamide—glaucoma	8.12e-05	0.00039	CcSEcCtD
Duloxetine—Anorexia—Clonidine—glaucoma	8.09e-05	0.000389	CcSEcCtD
Duloxetine—Asthenia—Dorzolamide—glaucoma	8.07e-05	0.000388	CcSEcCtD
Duloxetine—Asthenia—Travoprost—glaucoma	8.04e-05	0.000387	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—FAS—glaucoma	8.03e-05	0.00168	CbGpPWpGaD
Duloxetine—Palpitations—Betaxolol—glaucoma	8e-05	0.000385	CcSEcCtD
Duloxetine—Pruritus—Dorzolamide—glaucoma	7.96e-05	0.000383	CcSEcCtD
Duloxetine—Loss of consciousness—Betaxolol—glaucoma	7.96e-05	0.000383	CcSEcCtD
Duloxetine—Eye disorder—Timolol—glaucoma	7.94e-05	0.000382	CcSEcCtD
Duloxetine—Asthenia—Brinzolamide—glaucoma	7.94e-05	0.000382	CcSEcCtD
Duloxetine—Pruritus—Travoprost—glaucoma	7.93e-05	0.000381	CcSEcCtD
Duloxetine—Tinnitus—Timolol—glaucoma	7.92e-05	0.000381	CcSEcCtD
Duloxetine—Cough—Betaxolol—glaucoma	7.9e-05	0.00038	CcSEcCtD
Duloxetine—Nausea—Bimatoprost—glaucoma	7.9e-05	0.00038	CcSEcCtD
Duloxetine—Cardiac disorder—Timolol—glaucoma	7.89e-05	0.000379	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	7.85e-05	0.00165	CbGpPWpGaD
Duloxetine—Hypersensitivity—Pilocarpine—glaucoma	7.83e-05	0.000377	CcSEcCtD
Duloxetine—Pruritus—Brinzolamide—glaucoma	7.83e-05	0.000376	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—OPN4—glaucoma	7.81e-05	0.00164	CbGpPWpGaD
Duloxetine—Vomiting—Acetazolamide—glaucoma	7.8e-05	0.000375	CcSEcCtD
Duloxetine—Dizziness—Brimonidine—glaucoma	7.79e-05	0.000375	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—PTGFR—glaucoma	7.75e-05	0.00163	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Clonidine—glaucoma	7.74e-05	0.000372	CcSEcCtD
Duloxetine—Angiopathy—Timolol—glaucoma	7.71e-05	0.000371	CcSEcCtD
Duloxetine—Arthralgia—Betaxolol—glaucoma	7.71e-05	0.000371	CcSEcCtD
Duloxetine—Chest pain—Betaxolol—glaucoma	7.71e-05	0.000371	CcSEcCtD
Duloxetine—Myalgia—Betaxolol—glaucoma	7.71e-05	0.000371	CcSEcCtD
Duloxetine—Diarrhoea—Dorzolamide—glaucoma	7.7e-05	0.00037	CcSEcCtD
Duloxetine—Headache—Acetazolamide—glaucoma	7.69e-05	0.00037	CcSEcCtD
Duloxetine—Anxiety—Betaxolol—glaucoma	7.68e-05	0.00037	CcSEcCtD
Duloxetine—Insomnia—Clonidine—glaucoma	7.68e-05	0.000369	CcSEcCtD
Duloxetine—Immune system disorder—Timolol—glaucoma	7.68e-05	0.000369	CcSEcCtD
Duloxetine—Diarrhoea—Travoprost—glaucoma	7.66e-05	0.000369	CcSEcCtD
Duloxetine—Mediastinal disorder—Timolol—glaucoma	7.66e-05	0.000368	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	7.66e-05	0.000368	CcSEcCtD
Duloxetine—Asthenia—Pilocarpine—glaucoma	7.63e-05	0.000367	CcSEcCtD
Duloxetine—Paraesthesia—Clonidine—glaucoma	7.62e-05	0.000367	CcSEcCtD
Duloxetine—Discomfort—Betaxolol—glaucoma	7.62e-05	0.000366	CcSEcCtD
Duloxetine—Arrhythmia—Timolol—glaucoma	7.59e-05	0.000365	CcSEcCtD
Duloxetine—Diarrhoea—Brinzolamide—glaucoma	7.57e-05	0.000364	CcSEcCtD
Duloxetine—Somnolence—Clonidine—glaucoma	7.55e-05	0.000363	CcSEcCtD
Duloxetine—Dry mouth—Betaxolol—glaucoma	7.54e-05	0.000363	CcSEcCtD
Duloxetine—Pruritus—Pilocarpine—glaucoma	7.52e-05	0.000362	CcSEcCtD
Duloxetine—Alopecia—Timolol—glaucoma	7.51e-05	0.000361	CcSEcCtD
Duloxetine—Confusional state—Betaxolol—glaucoma	7.45e-05	0.000358	CcSEcCtD
Duloxetine—Mental disorder—Timolol—glaucoma	7.45e-05	0.000358	CcSEcCtD
Duloxetine—Dizziness—Dorzolamide—glaucoma	7.44e-05	0.000358	CcSEcCtD
Duloxetine—Rash—Brimonidine—glaucoma	7.43e-05	0.000357	CcSEcCtD
Duloxetine—Dermatitis—Brimonidine—glaucoma	7.42e-05	0.000357	CcSEcCtD
Duloxetine—Dizziness—Travoprost—glaucoma	7.41e-05	0.000356	CcSEcCtD
Duloxetine—Erythema—Timolol—glaucoma	7.4e-05	0.000356	CcSEcCtD
Duloxetine—Malnutrition—Timolol—glaucoma	7.4e-05	0.000356	CcSEcCtD
Duloxetine—Oedema—Betaxolol—glaucoma	7.39e-05	0.000355	CcSEcCtD
Duloxetine—Headache—Brimonidine—glaucoma	7.38e-05	0.000355	CcSEcCtD
Duloxetine—Decreased appetite—Clonidine—glaucoma	7.38e-05	0.000355	CcSEcCtD
Duloxetine—Infection—Betaxolol—glaucoma	7.34e-05	0.000353	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Clonidine—glaucoma	7.33e-05	0.000353	CcSEcCtD
Duloxetine—Fatigue—Clonidine—glaucoma	7.32e-05	0.000352	CcSEcCtD
Duloxetine—Dizziness—Brinzolamide—glaucoma	7.31e-05	0.000352	CcSEcCtD
Duloxetine—Nausea—Acetazolamide—glaucoma	7.29e-05	0.000351	CcSEcCtD
Duloxetine—Diarrhoea—Pilocarpine—glaucoma	7.27e-05	0.00035	CcSEcCtD
Duloxetine—Shock—Betaxolol—glaucoma	7.27e-05	0.00035	CcSEcCtD
Duloxetine—Tension—Timolol—glaucoma	7.26e-05	0.000349	CcSEcCtD
Duloxetine—Constipation—Clonidine—glaucoma	7.26e-05	0.000349	CcSEcCtD
Duloxetine—Pain—Clonidine—glaucoma	7.26e-05	0.000349	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—HDAC9—glaucoma	7.26e-05	0.00152	CbGpPWpGaD
Duloxetine—Nervous system disorder—Betaxolol—glaucoma	7.25e-05	0.000349	CcSEcCtD
Duloxetine—Dysgeusia—Timolol—glaucoma	7.25e-05	0.000348	CcSEcCtD
Duloxetine—Thrombocytopenia—Betaxolol—glaucoma	7.24e-05	0.000348	CcSEcCtD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	7.22e-05	0.00152	CbGpPWpGaD
Duloxetine—Tachycardia—Betaxolol—glaucoma	7.21e-05	0.000347	CcSEcCtD
Duloxetine—Nervousness—Timolol—glaucoma	7.19e-05	0.000346	CcSEcCtD
Duloxetine—Skin disorder—Betaxolol—glaucoma	7.18e-05	0.000345	CcSEcCtD
Duloxetine—Vomiting—Dorzolamide—glaucoma	7.15e-05	0.000344	CcSEcCtD
Duloxetine—Hyperhidrosis—Betaxolol—glaucoma	7.15e-05	0.000344	CcSEcCtD
Duloxetine—Rash—Dorzolamide—glaucoma	7.09e-05	0.000341	CcSEcCtD
Duloxetine—Dermatitis—Dorzolamide—glaucoma	7.09e-05	0.000341	CcSEcCtD
Duloxetine—Rash—Travoprost—glaucoma	7.06e-05	0.00034	CcSEcCtD
Duloxetine—Dermatitis—Travoprost—glaucoma	7.06e-05	0.000339	CcSEcCtD
Duloxetine—Headache—Dorzolamide—glaucoma	7.05e-05	0.000339	CcSEcCtD
Duloxetine—Anorexia—Betaxolol—glaucoma	7.05e-05	0.000339	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—PTGFR—glaucoma	7.03e-05	0.00148	CbGpPWpGaD
Duloxetine—Vomiting—Brinzolamide—glaucoma	7.03e-05	0.000338	CcSEcCtD
Duloxetine—Dizziness—Pilocarpine—glaucoma	7.03e-05	0.000338	CcSEcCtD
Duloxetine—Headache—Travoprost—glaucoma	7.02e-05	0.000338	CcSEcCtD
Duloxetine—Nausea—Brimonidine—glaucoma	7e-05	0.000337	CcSEcCtD
Duloxetine—Feeling abnormal—Clonidine—glaucoma	7e-05	0.000336	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—EDN1—glaucoma	6.98e-05	0.00146	CbGpPWpGaD
Duloxetine—Rash—Brinzolamide—glaucoma	6.97e-05	0.000335	CcSEcCtD
Duloxetine—Vision blurred—Timolol—glaucoma	6.97e-05	0.000335	CcSEcCtD
Duloxetine—Dermatitis—Brinzolamide—glaucoma	6.97e-05	0.000335	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC6A13—glaucoma	6.96e-05	0.00146	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Clonidine—glaucoma	6.94e-05	0.000334	CcSEcCtD
Duloxetine—Headache—Brinzolamide—glaucoma	6.93e-05	0.000333	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—glaucoma	6.92e-05	0.00145	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SMO—glaucoma	6.91e-05	0.00145	CbGpPWpGaD
Duloxetine—Angioedema—Timolol—glaucoma	6.76e-05	0.000325	CcSEcCtD
Duloxetine—Vomiting—Pilocarpine—glaucoma	6.76e-05	0.000325	CcSEcCtD
Duloxetine—Urticaria—Clonidine—glaucoma	6.74e-05	0.000324	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Betaxolol—glaucoma	6.73e-05	0.000324	CcSEcCtD
Duloxetine—Abdominal pain—Clonidine—glaucoma	6.71e-05	0.000323	CcSEcCtD
Duloxetine—Body temperature increased—Clonidine—glaucoma	6.71e-05	0.000323	CcSEcCtD
Duloxetine—Rash—Pilocarpine—glaucoma	6.7e-05	0.000322	CcSEcCtD
Duloxetine—Dermatitis—Pilocarpine—glaucoma	6.7e-05	0.000322	CcSEcCtD
Duloxetine—Insomnia—Betaxolol—glaucoma	6.69e-05	0.000322	CcSEcCtD
Duloxetine—Nausea—Dorzolamide—glaucoma	6.68e-05	0.000321	CcSEcCtD
Duloxetine—Headache—Pilocarpine—glaucoma	6.66e-05	0.00032	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—LRP12—glaucoma	6.66e-05	0.0014	CbGpPWpGaD
Duloxetine—Nausea—Travoprost—glaucoma	6.65e-05	0.00032	CcSEcCtD
Duloxetine—HTR2C—G alpha (q) signalling events—EDN1—glaucoma	6.65e-05	0.0014	CbGpPWpGaD
Duloxetine—Vertigo—Timolol—glaucoma	6.65e-05	0.00032	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1A—glaucoma	6.64e-05	0.00139	CbGpPWpGaD
Duloxetine—Paraesthesia—Betaxolol—glaucoma	6.64e-05	0.000319	CcSEcCtD
Duloxetine—Syncope—Timolol—glaucoma	6.64e-05	0.000319	CcSEcCtD
Duloxetine—Nausea—Brinzolamide—glaucoma	6.57e-05	0.000316	CcSEcCtD
Duloxetine—Palpitations—Timolol—glaucoma	6.54e-05	0.000314	CcSEcCtD
Duloxetine—Dyspepsia—Betaxolol—glaucoma	6.51e-05	0.000313	CcSEcCtD
Duloxetine—Loss of consciousness—Timolol—glaucoma	6.5e-05	0.000313	CcSEcCtD
Duloxetine—Cough—Timolol—glaucoma	6.46e-05	0.000311	CcSEcCtD
Duloxetine—Decreased appetite—Betaxolol—glaucoma	6.43e-05	0.000309	CcSEcCtD
Duloxetine—Hypertension—Timolol—glaucoma	6.39e-05	0.000307	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Betaxolol—glaucoma	6.38e-05	0.000307	CcSEcCtD
Duloxetine—Fatigue—Betaxolol—glaucoma	6.37e-05	0.000306	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—EDN1—glaucoma	6.34e-05	0.00133	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—OPN4—glaucoma	6.33e-05	0.00133	CbGpPWpGaD
Duloxetine—Constipation—Betaxolol—glaucoma	6.32e-05	0.000304	CcSEcCtD
Duloxetine—Pain—Betaxolol—glaucoma	6.32e-05	0.000304	CcSEcCtD
Duloxetine—Nausea—Pilocarpine—glaucoma	6.31e-05	0.000304	CcSEcCtD
Duloxetine—Chest pain—Timolol—glaucoma	6.3e-05	0.000303	CcSEcCtD
Duloxetine—Myalgia—Timolol—glaucoma	6.3e-05	0.000303	CcSEcCtD
Duloxetine—Arthralgia—Timolol—glaucoma	6.3e-05	0.000303	CcSEcCtD
Duloxetine—Anxiety—Timolol—glaucoma	6.28e-05	0.000302	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	6.26e-05	0.000301	CcSEcCtD
Duloxetine—Hypersensitivity—Clonidine—glaucoma	6.26e-05	0.000301	CcSEcCtD
Duloxetine—Discomfort—Timolol—glaucoma	6.22e-05	0.000299	CcSEcCtD
Duloxetine—Dry mouth—Timolol—glaucoma	6.16e-05	0.000296	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NGF—glaucoma	6.14e-05	0.00129	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NR3C1—glaucoma	6.11e-05	0.00128	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—C3—glaucoma	6.1e-05	0.00128	CbGpPWpGaD
Duloxetine—Asthenia—Clonidine—glaucoma	6.09e-05	0.000293	CcSEcCtD
Duloxetine—Feeling abnormal—Betaxolol—glaucoma	6.09e-05	0.000293	CcSEcCtD
Duloxetine—Confusional state—Timolol—glaucoma	6.09e-05	0.000293	CcSEcCtD
Duloxetine—Anaphylactic shock—Timolol—glaucoma	6.04e-05	0.00029	CcSEcCtD
Duloxetine—Oedema—Timolol—glaucoma	6.04e-05	0.00029	CcSEcCtD
Duloxetine—Pruritus—Clonidine—glaucoma	6.01e-05	0.000289	CcSEcCtD
Duloxetine—Infection—Timolol—glaucoma	6e-05	0.000289	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	5.98e-05	0.00126	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	5.95e-05	0.00125	CbGpPWpGaD
Duloxetine—Shock—Timolol—glaucoma	5.94e-05	0.000286	CcSEcCtD
Duloxetine—Nervous system disorder—Timolol—glaucoma	5.92e-05	0.000285	CcSEcCtD
Duloxetine—Urticaria—Betaxolol—glaucoma	5.87e-05	0.000282	CcSEcCtD
Duloxetine—Skin disorder—Timolol—glaucoma	5.87e-05	0.000282	CcSEcCtD
Duloxetine—Body temperature increased—Betaxolol—glaucoma	5.84e-05	0.000281	CcSEcCtD
Duloxetine—Hyperhidrosis—Timolol—glaucoma	5.84e-05	0.000281	CcSEcCtD
Duloxetine—Diarrhoea—Clonidine—glaucoma	5.81e-05	0.000279	CcSEcCtD
Duloxetine—HTR2A—G alpha (q) signalling events—EDN1—glaucoma	5.78e-05	0.00121	CbGpPWpGaD
Duloxetine—Anorexia—Timolol—glaucoma	5.76e-05	0.000277	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—OPN4—glaucoma	5.75e-05	0.00121	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.75e-05	0.00121	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTGFR—glaucoma	5.7e-05	0.0012	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTT1—glaucoma	5.68e-05	0.00119	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SMO—glaucoma	5.68e-05	0.00119	CbGpPWpGaD
Duloxetine—Dizziness—Clonidine—glaucoma	5.61e-05	0.00027	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—C3—glaucoma	5.54e-05	0.00116	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Timolol—glaucoma	5.5e-05	0.000265	CcSEcCtD
Duloxetine—HTR2A—GPCR downstream signaling—OPN4—glaucoma	5.5e-05	0.00115	CbGpPWpGaD
Duloxetine—Insomnia—Timolol—glaucoma	5.46e-05	0.000263	CcSEcCtD
Duloxetine—Hypersensitivity—Betaxolol—glaucoma	5.45e-05	0.000262	CcSEcCtD
Duloxetine—Paraesthesia—Timolol—glaucoma	5.42e-05	0.000261	CcSEcCtD
Duloxetine—Vomiting—Clonidine—glaucoma	5.4e-05	0.00026	CcSEcCtD
Duloxetine—Somnolence—Timolol—glaucoma	5.37e-05	0.000258	CcSEcCtD
Duloxetine—Rash—Clonidine—glaucoma	5.35e-05	0.000257	CcSEcCtD
Duloxetine—Dermatitis—Clonidine—glaucoma	5.35e-05	0.000257	CcSEcCtD
Duloxetine—Headache—Clonidine—glaucoma	5.32e-05	0.000256	CcSEcCtD
Duloxetine—Dyspepsia—Timolol—glaucoma	5.32e-05	0.000256	CcSEcCtD
Duloxetine—Asthenia—Betaxolol—glaucoma	5.3e-05	0.000255	CcSEcCtD
Duloxetine—Decreased appetite—Timolol—glaucoma	5.25e-05	0.000252	CcSEcCtD
Duloxetine—CYP1A2—Phase II conjugation—GSTM1—glaucoma	5.24e-05	0.0011	CbGpPWpGaD
Duloxetine—Pruritus—Betaxolol—glaucoma	5.23e-05	0.000252	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	5.23e-05	0.0011	CbGpPWpGaD
Duloxetine—Gastrointestinal disorder—Timolol—glaucoma	5.21e-05	0.000251	CcSEcCtD
Duloxetine—Fatigue—Timolol—glaucoma	5.21e-05	0.00025	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—NTRK2—glaucoma	5.19e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTGFR—glaucoma	5.18e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	5.17e-05	0.00108	CbGpPWpGaD
Duloxetine—Pain—Timolol—glaucoma	5.16e-05	0.000248	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.09e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SMO—glaucoma	5.09e-05	0.00107	CbGpPWpGaD
Duloxetine—Diarrhoea—Betaxolol—glaucoma	5.06e-05	0.000243	CcSEcCtD
Duloxetine—Nausea—Clonidine—glaucoma	5.04e-05	0.000243	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—OPN4—glaucoma	5e-05	0.00105	CbGpPWpGaD
Duloxetine—Feeling abnormal—Timolol—glaucoma	4.98e-05	0.000239	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—glaucoma	4.97e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTGFR—glaucoma	4.95e-05	0.00104	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Timolol—glaucoma	4.94e-05	0.000237	CcSEcCtD
Duloxetine—HTR2C—Signaling Pathways—LRP12—glaucoma	4.9e-05	0.00103	CbGpPWpGaD
Duloxetine—Dizziness—Betaxolol—glaucoma	4.89e-05	0.000235	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—glaucoma	4.87e-05	0.00102	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTT1—glaucoma	4.81e-05	0.00101	CbGpPWpGaD
Duloxetine—Urticaria—Timolol—glaucoma	4.8e-05	0.000231	CcSEcCtD
Duloxetine—Body temperature increased—Timolol—glaucoma	4.77e-05	0.00023	CcSEcCtD
Duloxetine—Abdominal pain—Timolol—glaucoma	4.77e-05	0.00023	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	4.7e-05	0.000987	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	4.7e-05	0.000987	CbGpPWpGaD
Duloxetine—Vomiting—Betaxolol—glaucoma	4.7e-05	0.000226	CcSEcCtD
Duloxetine—Rash—Betaxolol—glaucoma	4.66e-05	0.000224	CcSEcCtD
Duloxetine—Dermatitis—Betaxolol—glaucoma	4.66e-05	0.000224	CcSEcCtD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—glaucoma	4.65e-05	0.000975	CbGpPWpGaD
Duloxetine—Headache—Betaxolol—glaucoma	4.63e-05	0.000223	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—OPN4—glaucoma	4.61e-05	0.000968	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—EDN1—glaucoma	4.56e-05	0.000956	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP1B1—glaucoma	4.53e-05	0.00095	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTGFR—glaucoma	4.5e-05	0.000944	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	4.47e-05	0.000937	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NGFR—glaucoma	4.46e-05	0.000935	CbGpPWpGaD
Duloxetine—Hypersensitivity—Timolol—glaucoma	4.45e-05	0.000214	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—SMO—glaucoma	4.42e-05	0.000927	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	4.41e-05	0.000925	CbGpPWpGaD
Duloxetine—Nausea—Betaxolol—glaucoma	4.39e-05	0.000211	CcSEcCtD
Duloxetine—Asthenia—Timolol—glaucoma	4.33e-05	0.000208	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—HEYL—glaucoma	4.29e-05	0.0009	CbGpPWpGaD
Duloxetine—Pruritus—Timolol—glaucoma	4.27e-05	0.000205	CcSEcCtD
Duloxetine—HTR2A—Signaling Pathways—LRP12—glaucoma	4.26e-05	0.000893	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NTRK1—glaucoma	4.23e-05	0.000889	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—glaucoma	4.17e-05	0.000876	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTGFR—glaucoma	4.15e-05	0.000872	CbGpPWpGaD
Duloxetine—Diarrhoea—Timolol—glaucoma	4.13e-05	0.000199	CcSEcCtD
Duloxetine—Dizziness—Timolol—glaucoma	3.99e-05	0.000192	CcSEcCtD
Duloxetine—CYP2D6—Metabolism—CA5A—glaucoma	3.98e-05	0.000836	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NARFL—glaucoma	3.98e-05	0.000836	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—C3—glaucoma	3.98e-05	0.000835	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	3.91e-05	0.000821	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN2B—glaucoma	3.9e-05	0.000819	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	3.85e-05	0.000808	CbGpPWpGaD
Duloxetine—Vomiting—Timolol—glaucoma	3.84e-05	0.000185	CcSEcCtD
Duloxetine—CYP1A2—Biological oxidations—CYP1B1—glaucoma	3.84e-05	0.000805	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	3.83e-05	0.000803	CbGpPWpGaD
Duloxetine—Rash—Timolol—glaucoma	3.81e-05	0.000183	CcSEcCtD
Duloxetine—Dermatitis—Timolol—glaucoma	3.8e-05	0.000183	CcSEcCtD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP1B1—glaucoma	3.78e-05	0.000794	CbGpPWpGaD
Duloxetine—Headache—Timolol—glaucoma	3.78e-05	0.000182	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—EDN1—glaucoma	3.74e-05	0.000786	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTM1—glaucoma	3.62e-05	0.00076	CbGpPWpGaD
Duloxetine—Nausea—Timolol—glaucoma	3.59e-05	0.000173	CcSEcCtD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	3.58e-05	0.000752	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	3.57e-05	0.000749	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SMO—glaucoma	3.55e-05	0.000744	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NGF—glaucoma	3.44e-05	0.000722	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—OPN4—glaucoma	3.4e-05	0.000713	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NARFL—glaucoma	3.37e-05	0.000708	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA5A—glaucoma	3.37e-05	0.000708	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—EDN1—glaucoma	3.36e-05	0.000704	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	3.35e-05	0.000704	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—glaucoma	3.35e-05	0.000704	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	3.34e-05	0.000701	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—C3—glaucoma	3.27e-05	0.000687	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RPTOR—glaucoma	3.25e-05	0.000682	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HEYL—glaucoma	3.16e-05	0.000663	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NCK2—glaucoma	3.15e-05	0.000661	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTM1—glaucoma	3.07e-05	0.000644	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTGFR—glaucoma	3.06e-05	0.000642	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—APOE—glaucoma	3.05e-05	0.000639	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTM1—glaucoma	3.02e-05	0.000635	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CAV1—glaucoma	3.02e-05	0.000633	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—glaucoma	3e-05	0.000631	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—OPN4—glaucoma	2.95e-05	0.000619	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—glaucoma	2.93e-05	0.000615	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—C3—glaucoma	2.93e-05	0.000615	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—EDN1—glaucoma	2.91e-05	0.000611	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—FN1—glaucoma	2.87e-05	0.000603	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—BAD—glaucoma	2.84e-05	0.000596	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HEYL—glaucoma	2.74e-05	0.000576	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HDAC9—glaucoma	2.68e-05	0.000562	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTGFR—glaucoma	2.66e-05	0.000558	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SMO—glaucoma	2.61e-05	0.000548	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—EDN1—glaucoma	2.57e-05	0.00054	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—C3—glaucoma	2.55e-05	0.000534	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—glaucoma	2.51e-05	0.000527	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RPTOR—glaucoma	2.39e-05	0.000502	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EDN1—glaucoma	2.34e-05	0.000491	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NCK2—glaucoma	2.32e-05	0.000487	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOS3—glaucoma	2.28e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SMO—glaucoma	2.27e-05	0.000476	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—C3—glaucoma	2.25e-05	0.000472	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMO—glaucoma	2.1e-05	0.00044	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RPTOR—glaucoma	2.08e-05	0.000436	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—C3—glaucoma	2.04e-05	0.000429	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCK2—glaucoma	2.01e-05	0.000423	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN1B—glaucoma	1.98e-05	0.000415	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HDAC9—glaucoma	1.97e-05	0.000414	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA1—glaucoma	1.95e-05	0.000408	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK2—glaucoma	1.92e-05	0.000402	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—EDN1—glaucoma	1.9e-05	0.000398	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CTSA—glaucoma	1.88e-05	0.000395	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—glaucoma	1.83e-05	0.000384	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA2—glaucoma	1.78e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EDN1—glaucoma	1.72e-05	0.000361	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HDAC9—glaucoma	1.71e-05	0.000359	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—C3—glaucoma	1.66e-05	0.000348	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA1—glaucoma	1.65e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—EDN1—glaucoma	1.65e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGFR—glaucoma	1.64e-05	0.000345	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—glaucoma	1.64e-05	0.000345	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CTSA—glaucoma	1.6e-05	0.000335	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK1—glaucoma	1.56e-05	0.000328	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMO—glaucoma	1.54e-05	0.000324	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA2—glaucoma	1.51e-05	0.000316	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—C3—glaucoma	1.5e-05	0.000316	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EDN1—glaucoma	1.5e-05	0.000314	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.47e-05	0.000309	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.47e-05	0.000309	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN2B—glaucoma	1.44e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—C3—glaucoma	1.44e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK2—glaucoma	1.41e-05	0.000296	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EDN1—glaucoma	1.38e-05	0.00029	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMO—glaucoma	1.34e-05	0.000281	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—C3—glaucoma	1.31e-05	0.000274	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGF—glaucoma	1.27e-05	0.000266	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TXN—glaucoma	1.25e-05	0.000263	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—glaucoma	1.24e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—glaucoma	1.23e-05	0.000257	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGFR—glaucoma	1.21e-05	0.000254	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—C3—glaucoma	1.21e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK1—glaucoma	1.15e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—glaucoma	1.12e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—glaucoma	1.11e-05	0.000234	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TXN—glaucoma	1.06e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN2B—glaucoma	1.06e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FN1—glaucoma	1.06e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGFR—glaucoma	1.05e-05	0.000221	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BAD—glaucoma	1.05e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—glaucoma	1.02e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK1—glaucoma	9.99e-06	0.00021	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—glaucoma	9.72e-06	0.000204	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	9.69e-06	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	9.6e-06	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGF—glaucoma	9.35e-06	0.000196	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—glaucoma	9.21e-06	0.000193	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C3—glaucoma	8.89e-06	0.000186	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—glaucoma	8.83e-06	0.000185	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—glaucoma	8.42e-06	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—glaucoma	8.27e-06	0.000174	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—glaucoma	8.23e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—glaucoma	8.2e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGF—glaucoma	8.12e-06	0.00017	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—glaucoma	7.8e-06	0.000164	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—glaucoma	7.74e-06	0.000163	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCA1—glaucoma	7.74e-06	0.000163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C3—glaucoma	7.72e-06	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—glaucoma	7.71e-06	0.000162	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—glaucoma	7.29e-06	0.000153	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—glaucoma	7.18e-06	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—glaucoma	7.12e-06	0.000149	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—glaucoma	6.77e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—glaucoma	6.75e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—glaucoma	6.69e-06	0.00014	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.64e-06	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCA1—glaucoma	6.56e-06	0.000138	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—glaucoma	6.56e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—glaucoma	6.2e-06	0.00013	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—glaucoma	6.19e-06	0.00013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—glaucoma	6.06e-06	0.000127	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—glaucoma	5.47e-06	0.000115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—glaucoma	5.38e-06	0.000113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—glaucoma	5.37e-06	0.000113	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—glaucoma	5.24e-06	0.00011	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—glaucoma	5.09e-06	0.000107	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—glaucoma	5.05e-06	0.000106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—glaucoma	4.97e-06	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—glaucoma	4.66e-06	9.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—glaucoma	4.63e-06	9.73e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—glaucoma	4.58e-06	9.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—glaucoma	4.47e-06	9.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—glaucoma	4.32e-06	9.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—glaucoma	4.31e-06	9.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—glaucoma	4.28e-06	8.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—glaucoma	3.88e-06	8.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—glaucoma	3.82e-06	8.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—glaucoma	3.49e-06	7.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—glaucoma	3.37e-06	7.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—glaucoma	3.23e-06	6.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—glaucoma	2.96e-06	6.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—glaucoma	2.93e-06	6.15e-05	CbGpPWpGaD
